inorganic chemistry

TABLE VII

A

NIMAL

-M

ODEL

,T

UMOR

• TO

-N

ORMAL

T

ISSUE

R

ATIOS

,L

ASER

L

IGHT

D

OSE

,B

LOOD

C

LEARANCE

K

INETICS

,

AND

T

UMOR

G

ROWTH

D

ELAYS TO

P

REDETERMINED

S

IZES IN

PDT

Sensitizer

Animal, tumor

Tumor/skin

Tumor/muscle

Light dose(J/cm

2 )

Clearancehalf-life (h)

Tumor growthdelay (days)

Photofrin

a

Nude, HT29

1.05

4.7

100

23

b

8

Foscan

c

BDIX, LSBD

3.09

7.57

50

80

b

7

Stakel

d

Nude, M2R



1

30

0.028

20

H

BPurhep 2

e

C3H, RIF-1

2.8

135

18

H

DOHPTMB 2

f

C57BL/6, B16F10

120

6

H

TClPBOH 2

g

DBA, S91

5.3

3

108

h 5

27

aFrom Ref. (

111

), tumor-to-normal tissue ratios measured 24-h post 30-mg/kg i.p. injection, endpoint of tumor growth 3 cm

3.

bNoncompartimental analysis of biological half-life in BDIX rats, from

Ref. (

112

).

cFrom Ref. (

112

), tumor-to-normal tissue ratios measured 24-h post 0.3-mg/kg i.v. injection, endpoint of tumor growth 1.8 cm

3.

dFrom Ref. (

113

), tumor-to-normal tissue ratios measured a few minutes post 6-mg/kg i.v. injection, endpoint of tumor growth 1.8 cm

3 ; a drug

dose of 9 mg/kg i.v. further delays tumor growth.eFrom Ref. (

101

), PDT performed 15-min post 0.4-

mmol/kg i.p. injection, endpoint of tumor growth 0.4 cm

3.

fFrom Ref. (

85

), tumor-to-normal tissue ratios measured 24-h post 5 mg/kg i.v. injection, endpoint of tumor growth 1 cm

3.

gFrom

Ref. (

105

), tumor-to-normal tissue ratios measured 24-h post 10-mg/kg i.p. injection, endpoint of tumor growth 0.7 cm

3.

hThere is an initial increase in the concentration of the sensitizer in the blood, followed by a decrease with a half-life of ca. 5 h.